Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2026 | January 06, 2026 |
| Perspective Therapeutics, Inc.CATX · Entity 694 | Director | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2036-01-01 | Direct | 24,400 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This stock option becomes fully exercisable on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This stock option becomes fully exercisable on the first anniversary of the grant date.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 50,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:38 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001748615-26-000002 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004357 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2036-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000950170-25-033626 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-03 F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025. F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000950170-25-001107 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2035-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:15 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 23,000 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0000950170-24-076727 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000950170-24-001827 · ownership.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2034-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:34 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-23-034475 · rdgdoc.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,037,471 Underlying: Common Stock · 230,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: 100% vests 12/12/2024. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:35 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001437749-23-004436 · rdgdoc.xml · derivative · entry 2 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,807,471 Underlying: Common Stock · 230,000 shares Expires 2033-02-21 F2 · derivative.exercise_date: 100% vests 2/21/2024. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:35 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 470,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001437749-23-004436 · rdgdoc.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,577,471 Underlying: Common Stock · 470,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: Vest monthly over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:11 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-001796 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2023. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:06 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 28,000 | $3.75 | $105,000.00 |
DisclosureSEC source: 0001209191-22-032800 · doc4.xml · nonDerivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-22-001051 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000705 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:18 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001209191-20-028490 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2030-05-11 F1 · shares: Represents a stock option award granted on May 11, 2020 pursuant to the Issuer's 2016 Omnibus Incentive Plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002064 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:40 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001333 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 21:09 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001209191-18-045015 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-07-31 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning January 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.